Company Overview and News

 
Former Senate President Joins Medical Cannabis Payment Solutions (REFG) Advisory Board

2018-07-16 globenewswire
LAS VEGAS, July 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a leader in technological solutions for the medical cannabis industry, announced today the company has added Mike Haridopolos, the former president of the Florida State Senate, to the company’s advisory board. Haridopolos joins former Oregon State Sen. Bruce Starr, former U.S. vice presidential Libertarian candidate James Gray, former New Mexico Gov.
ABCO REFG

 
Medical Cannabis Payment Solutions (REFG) Finalizing Agreement to Deploy Groundbreaking Mobile Hemp CBD Extraction Labs

2018-07-09 globenewswire
LAS VEGAS, July 09, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, today announces it has reached an agreement in principle that will result in the nation’s largest mobile hemp CBD processing service.
REFG

 
Medical Cannabis Payment Solutions Plans to Register for Growing License in Vermont, Acquire Property

2018-06-26 globenewswire
LAS VEGAS, June 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (OTC:REFG), a leader in technological solutions for the medical cannabis industry, announced today the company is working on growing industrial hemp as part of Vermont’s industrial hemp program. The company is looking at multiple properties to begin growing and anticipates its first harvest will be in 2019.
REFG

 
Medical Cannabis Payment Solutions’ SpeedyGrow Featured on KREX News Story

2018-06-07 globenewswire
LAS VEGAS, June 07, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced that its subsidiary, SpeedyGrow, was featured on KREX’s news story about CBD and hemp. KREX is the CBS-affiliated television station in Grand Junction, Colorado.
REFG

20
Cannabis Sativa Inc. Makes Huge Losses On Little Revenue. What Is Going On Here?

2018-05-30 seekingalpha - 1
If you are into the marijuana sector hype, it might be tempting to scoop up one of the smaller players exposed to different use cases for legal cannabis. The company has a portfolio of these, which I'll quickly present later. However, I strongly feel there are too many warning signs concerning Cannabis Sativa Inc. (OTCQB:CBDS) for a prudent investor to take a stake.
TWMJF ACB WEED ACBFF REFG CGC CBDS

 
Medical Cannabis Payment Solutions Announces Acquisition of 40 Acres to Grow Hemp

2018-05-29 globenewswire
LAS VEGAS, May 29, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that it has acquired 40 acres of agricultural land to cultivate hemp as part of Utah’s recently passed law, H.B. 302. The company will seek a license to grow hemp as part of the state’s Department of Agriculture and Food licensing program.
REFG

 
Medical Cannabis Payment Solutions Announces Acquisition, State License

2018-05-17 globenewswire
LAS VEGAS, May 17, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that it has acquired SpeedyGrow, a Wyoming corporation with licenses to grow and process hemp in the state of Colorado. The company extracts full spectrum CBD.
REFG

 
Medical Cannabis Payment Solutions to Offer Bank Accounts for State Licensed Medical Marijuana Establishments

2018-04-18 globenewswire
LAS VEGAS, April 18, 2018 (GLOBE NEWSWIRE) -- via NetworkWire --Medical Cannabis Payment Solutions (OTC:REFG), a leader in technological solutions for the medical cannabis industry, announced today the company will begin offering bank accounts to qualified and licensed medical marijuana establishments. The company’s website, www.take.green, will be updated shortly to allow online applications for banking services.
REFG

 
Medical Cannabis Payment Solutions’ (REFG) ‘Green’ Sees Dramatic Increase in Applications Since March 16 Launch on Take.green Website

2018-04-04 globenewswire
LAS VEGAS, April 04, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that state-licensed marijuana establishments may sign up via its website for its banking and financial processing system. The company, which has been working with targeted establishments, has now made its services available to the entire industry.
REFG

 
Medical Cannabis Payment Solutions Fully Launches Payment System, Establishments May Now Enroll

2018-03-16 globenewswire
LAS VEGAS, March 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation that specializes in state-of-the-art financial services structured to serve the medical cannabis and banking industry, announced today that state licensed marijuana establishments may sign up via its website for its banking and financial processing system. The company, which has been working with targeted establishments, has now made its services available to the entire industry.
REFG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...